Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J.
Point Therapeutics, Inc., Boston, MA, United States
Search grants from Margaret Uprichard
Search grants from Point Therapeutics, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Molecular Epidemiology, Virulence, and Genomic Characterization of Ureaplasmas
Adenosine A1 and A2 Receptors in the Myocardium
Hypothalamic Neuropeptide Pathways Mediating Sympathetic Responses to Leptin
Cellular Cadmium Transport in Cultured Kidney Cells
Mechanistic Approaches to Carcinogenesis
Recently added grants:
Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.
Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease
A novel technology to assess chronic toxicity in genetically diverse nematode populations
In Vitro Toxicity Testing at Massive Scale in Diverse Primary Human Cells
BP-ENDURE at the University of Nevada
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
5R01FD003021-02
Application #
7128133
Study Section
Special Emphasis Panel (ZFD1-OPD (01))
Program Officer
Ganti, Usha
Project Start
2005-09-30
Project End
2007-06-30
Budget Start
2006-09-30
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
Point Therapeutics, Inc.
Department
Type
DUNS #
829400415
City
Boston
State
MA
Country
United States
Zip Code
02110
Related projects
NIH 2006
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
NIH 2005
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
Comments
Be the first to comment on Margaret Uprichard's grant